Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Keeping Track: New Drugs For Glaucoma, Sickle Cell Submitted; IDegLira, Brineura Reviews Extended; Keytruda Advances In First-Line NSCLC

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles
Quick Acting Antibiotic Lends Promise To Destiny's Future
Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says
Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems
Does CheckMate 026 Take Bristol Out Of The End Game?
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
Units, Clicks? Novel Diabetes Combos Need A Measurement
Will Dynavax’ HBV Vaccine Resubmission Make The Safety Grade?
Aerie ROCKETS On Glaucoma Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register